Antibody-Dependent Enhancement of SARS-CoV-2 Infection Is Mediated by the IgG Receptors FcγRIIA and FcγRIIIA but Does Not Contribute to Aberrant Cytokine Production by Macrophages

Viruses infect cells mainly via specific receptors at the cell surface. Antibody-dependent enhancement (ADE) of infection is an alternative mechanism of infection for viruses to infect immune cells that is mediated by antibodies and IgG receptors (FcγRs). ABSTRACT The coronavirus disease 2019 (COVID-19) pandemic has raised concerns about the detrimental effects of antibodies. Antibody-dependent enhancement (ADE) of infection is one of the biggest concerns in terms of not only the antibody reaction to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) upon reinfection with the virus but also the reaction to COVID-19 vaccines. In this study, we evaluated ADE of infection by using COVID-19 convalescent-phase plasma and BHK cells expressing human Fcγ receptors (FcγRs). We found that FcγRIIA and FcγRIIIA mediated modest ADE of infection against SARS-CoV-2. Although ADE of infection was observed in monocyte-derived macrophages infected with SARS-CoV-2, including its variants, proinflammatory cytokine/chemokine expression was not upregulated in macrophages. SARS-CoV-2 infection thus produces antibodies that elicit ADE of infection, but these antibodies do not contribute to excess cytokine production by macrophages. IMPORTANCE Viruses infect cells mainly via specific receptors at the cell surface. Antibody-dependent enhancement (ADE) of infection is an alternative mechanism of infection for viruses to infect immune cells that is mediated by antibodies and IgG receptors (FcγRs). Because ADE of infection contributes to the pathogenesis of some viruses, such as dengue virus and feline coronavirus, it is important to evaluate the precise mechanism of ADE and its contribution to the pathogenesis of SARS-CoV-2. Here, using convalescent-phase plasma from COVID-19 patients, we found that two types of FcγRs, FcγRIIA and FcγRIIIA, mediate ADE of SARS-CoV-2 infection. Although ADE of infection was observed for SARS-CoV-2 and its recent variants, proinflammatory cytokine production in monocyte-derived macrophages was not upregulated. These observations suggest that SARS-CoV-2 infection produces antibodies that elicit ADE of infection, but these antibodies may not be involved in aberrant cytokine release by macrophages during SARS-CoV-2 infection.

[1]  J. Fantini,et al.  Longitudinal study of a SARS-CoV-2 infection in an immunocompromised patient with X-linked agammaglobulinemia , 2021, Journal of Infection.

[2]  D. Standley,et al.  An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies , 2021, Cell.

[3]  A. Iafrate,et al.  Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity , 2021, Cell.

[4]  H. Jäck,et al.  SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies , 2021, Cell.

[5]  C. Creech,et al.  SARS-CoV-2 Vaccines. , 2021, JAMA.

[6]  Y. Kawaoka,et al.  Antibody titers against SARS-CoV-2 decline, but do not disappear for several months , 2021, EClinicalMedicine.

[7]  Bjoern Peters,et al.  Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , 2021, Science.

[8]  G. Zimmer,et al.  No Evidence for Human Monocyte-Derived Macrophage Infection and Antibody-Mediated Enhancement of SARS-CoV-2 Infection , 2020, bioRxiv.

[9]  S. Perlman,et al.  SARS-CoV-2-induced immune activation and death of monocyte-derived human macrophages and dendritic cells. , 2020, The Journal of infectious diseases.

[10]  F. Wu,et al.  Antibody-dependent enhancement (ADE) of SARS-CoV-2 infection in recovered COVID-19 patients: studies based on cellular and structural biology analysis , 2020, medRxiv.

[11]  F. Krammer SARS-CoV-2 vaccines in development , 2020, Nature.

[12]  S. Kent,et al.  Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies , 2020, Nature Microbiology.

[13]  M. Nandi,et al.  ADE and hyperinflammation in SARS-CoV2 infection- comparison with dengue hemorrhagic fever and feline infectious peritonitis , 2020, Cytokine.

[14]  J. Ravetch,et al.  The role of IgG Fc receptors in antibody-dependent enhancement , 2020, Nature Reviews Immunology.

[15]  Nicolas Carlier,et al.  Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients , 2020, Science.

[16]  R. Spreafico,et al.  A perspective on potential antibody-dependent enhancement of SARS-CoV-2 , 2020, Nature.

[17]  L. Montaner,et al.  Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts , 2020, Journal of leukocyte biology.

[18]  Malik Peiris,et al.  Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures , 2020, The Lancet Respiratory Medicine.

[19]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[20]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[21]  H. Katoh,et al.  Development of Genetic Diagnostic Methods for Detection for Novel Coronavirus 2019(nCoV-2019) in Japan , 2020 .

[22]  J. Luban SARS-CoV-2 , 2020 .

[23]  Qin Ning,et al.  Clinical and immunological features of severe and moderate coronavirus disease 2019 , 2020 .

[24]  Lilin Zhang,et al.  The alternatively spliced porcine Fc&ggr;RI regulated PRRSV‐ADE infection and proinflammatory cytokine production , 2019, Developmental and comparative immunology.

[25]  P. Charneau,et al.  A Japanese Encephalitis Virus Vaccine Inducing Antibodies Strongly Enhancing In Vitro Infection Is Protective in Pigs , 2017, Viruses.

[26]  J. Taubenberger,et al.  IgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity , 2017, Science.

[27]  P. Shi,et al.  A novel reporter system for neutralizing and enhancing antibody assay against dengue virus , 2014, BMC Microbiology.

[28]  P. Bruhns Properties of mouse and human IgG receptors and their contribution to disease models. , 2012, Blood.

[29]  W. Ouwehand,et al.  The Fc-receptor III of cultured human monocytes. Structural similarity with FcRIII of natural killer cells and role in the extracellular lysis of sensitized erythrocytes. , 1990, Journal of immunology.